Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Korean Cannabinoid Association Wants to Leverage Blockchain for Cannabidiol Clinical Trials

Published 08/10/2018, 02:24 PM
Updated 08/10/2018, 03:40 PM
 Korean Cannabinoid Association Wants to Leverage Blockchain for Cannabidiol Clinical Trials

The Korean Cannabinoid Association (KCA) said at a conference in Seoul on Monday that it intended to initiate a project to carry out clinical pilots related to cannabidiol (CBD), a constituent of cannabis that is used in multiple sclerosis and epilepsy therapies among others. The KCA will launch the project via Prasm, a decentralized bioinformatic network that leverages artificial intelligence (AI) and blockchain technologies.

Kwon Yong-hyun, director of Prasm and president of the KCA, commented on the project:

“Due to the prejudice that hemp is a drug, Korean medical society has been reluctant to conduct any clinical studies that could prove the therapeutic benefits of medical hemp.”

“We are aware that the majority of the public is concern...


This article appeared first on Cryptovest

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.